Find clinical trials

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread. HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2. Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles. Metastatic means the cancer has spread to other parts of the body. Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. This study consists of a 16-week Double-blind Period and a 100-week Longterm Extension (LTE) composed of a 40-week Main Extension and a 60-week Optional Extension. Each participant will participate in the study for approximately 135 weeks from the time the participant provides documented informed consent through the final contact. (including screening & follow up). There will be 147 participants across 70 centers worldwide.

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT).

This study investigates the safety and effectiveness of treatment with epcoritamab (Epkinly) following venatoclax-obinutuzumab in previously untreated patients with a type of CLL, which has at increased risk of disease coming back after treatment including: those with detectable MRD (measurable residual disease - an accurate test to detect very small amounts of CLL or SLL) following frontline ven-obi, or those with high-risk CLL genomics (changes in the genetic code in the CLL cells that are known to lead to the disease coming back sooner after completing ven-obi). The study compares outcomes to previously published clinical trial data from patients treated with ven-obi alone.

Non fasting blood samples are collected during the patients clinically indicated right heart catheterisation procedure. Blood is taken from the coronary sinus, pulmonary, hepatic and renal vein and from an arterial site. An echocardiogram is performed if the patient has not had one within the past 3 months. A 6 WMT and QOL questionnaires, ECG may also be performed.